Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)20.15
  • Today's Change0.33 / 1.66%
  • Shares traded455.50k
  • 1 Year change-72.40%
  • Beta--
Data delayed at least 15 minutes, as of May 27 2022 09:08 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Everest Medicines Ltd is a China-based company principally engaged in the licensing, clinical development and commercialization of therapies to address critical unmet medical needs. The Company is focusing on the research and development of innovative drug candidate. The Company built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The Company mainly provides its products and services in Greater China and other emerging Asia Pacific markets.

  • Revenue in HKD (TTM)62.91k
  • Net income in HKD-1.18bn
  • Incorporated2017
  • Employees405.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Peijia Medical Ltd159.05m-668.93m4.32bn689.00--1.22--27.14-1.01-1.010.24045.240.04520.89464.55230,848.50-19.00---19.53--70.06---420.57--19.88-23.510.0025--253.21--72.24------
Yichang Hec Changjiang Pharmactcl Co Ltd1.06bn-684.58m4.34bn3.62k--0.6412--4.08-0.778-0.7781.217.690.09091.311.95294,389.60-5.8510.68-8.2314.8752.9382.48-64.3227.101.44-2.490.346638.26-61.08-0.5958-170.00--27.36--
VIVA Biotech Holdings2.45bn334.98m4.43bn2.13k23.770.96228.431.810.09640.09641.242.380.25987.335.661,152,394.003.712.394.142.6330.9437.4314.2810.181.894.530.404222.00201.9085.23174.3263.68138.39--
China Shineway Pharmaceutical Group Ltd.3.76bn648.49m4.87bn3.45k6.860.70855.661.300.85880.85884.978.310.44721.588.76--7.726.699.187.7574.7772.8317.2717.684.65--0.002549.6221.3810.0988.68-1.13--10.72
SciClone Pharmaceuticals (Holdings) Ltd2.93bn1.08bn5.60bn890.005.242.044.661.911.561.564.224.020.72523.385.783,296,499.0026.59--40.14--76.75--36.66--2.9571.340.335--31.27--22.51------
Frontage Holdings Corp1.45bn144.65m5.62bn1.32k39.642.2116.723.880.06840.06840.68431.220.4297141.016.491,095,122.004.416.985.148.2836.1637.3110.2613.512.8810.880.15190.0046.6030.557.4520.5665.98--
CK Life Sciences Intl (Holdings) Inc5.40bn162.80m5.86bn1.86k36.011.3021.161.090.01690.01690.56210.46860.45572.885.512,912,298.001.371.951.572.5130.1731.393.014.200.92312.870.579948.489.302.1030.00-8.440.67610.00
CStone Pharmaceuticals1.30bn-1.54bn5.99bn264.00--2.19--4.60-1.37-1.371.172.300.4281----5,274,235.00-50.67---59.98--75.62---118.36--5.63-4.570.0402------40.98------
Everest Medicines Ltd62.91k-1.18bn6.07bn405.00--0.8764--96,485.41-4.01-4.010.000222.990.00001--0.0035155.33-14.28---14.76--57.41---1,867,998.00--9.94--0.0799------82.17------
China Isotope & Radiation Corp5.99bn391.13m6.20bn3.12k15.851.276.121.031.221.2218.7315.220.52332.971.971,920,552.006.857.7414.2515.4063.0366.6013.0814.671.50--0.124432.9820.3416.8357.205.0827.70--
CARsgen Therapeutics Holdings Ltd30.07m-5.53bn6.35bn573.00--1.81--211.19-23.67-23.670.07776.15------52,479.45--------100.00---18,379.97------0.1014-------345.88------
Keymed Biosciences Inc128.46m-4.53bn6.38bn325.00--1.50--49.65-21.54-21.540.798615.20------395,253.30--------84.40---3,530.12--31.81-800.030.0105-------374.88------
Sirnaomics Ltd0.00-1.67bn6.80bn175.00--4.05-----91.17-91.170.0018.86------0.00-------------------296.440.0686-------386.77------
New Horizon Health Ltd247.85m-3.59bn6.96bn804.00--2.81--28.09-10.53-10.530.65485.760.13421.792.24308,277.20-194.54---218.67--72.68---1,450.14--10.34-166.820.0547--201.50---291.18------
Tong Ren Tang Technologies Co., Ltd.6.29bn590.92m7.43bn3.97k12.571.075.761.180.46140.46144.915.440.47931.114.831,586,301.007.698.7512.9213.7942.4346.2716.0517.792.1531.360.167738.8417.212.978.49-3.16-18.23-0.5399
Ocumension Therapeutics65.41m-302.88m7.87bn244.00--2.17--120.29-0.4947-0.49470.10775.430.01894.791.21268,061.50-8.77---9.25--65.78---463.06--8.48--0.0036--328.73--88.52------
Data as of May 27 2022. Currency figures normalised to Everest Medicines Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

23.86%Per cent of shares held by top holders
HolderShares% Held
RA Capital Management LPas of 25 Jan 202224.25m8.05%
Janchor Partners Ltd.as of 31 Dec 202017.42m5.78%
Wellington Management Co. LLPas of 21 Mar 202213.88m4.61%
Janus Henderson Investors US LLCas of 31 Mar 20222.97m0.99%
GIC Pte Ltd. (Investment Management)as of 08 Oct 20202.82m0.94%
Candriam Belgium SAas of 31 Dec 20212.48m0.82%
The Vanguard Group, Inc.as of 05 May 20222.47m0.82%
BlackRock Advisors LLCas of 30 Apr 20222.06m0.69%
Columbia Management Investment Advisers LLCas of 31 Dec 20211.94m0.64%
BlackRock Fund Advisorsas of 03 May 20221.58m0.53%
More ▼
Data from 31 Mar 2022 - 19 May 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.